- In March 2024, GE HealthCare announced the global expansion of its BiliSoft 3.0 Phototherapy System, an advanced LED-based solution designed to offer effective treatment for neonatal jaundice while maximizing infant comfort and caregiver convenience. The system includes enhanced portability and reduced light scatter, making it more efficient in both hospital and home settings. This launch demonstrates GE HealthCare’s ongoing commitment to improving neonatal outcomes through innovative, non-invasive therapeutic solutions
- In February 2024, Draegerwerk AG & Co. KGaA introduced a next-generation transcutaneous bilirubin meter, JM-300, aimed at delivering fast, accurate, and non-invasive bilirubin assessments. The device is designed for point-of-care use in hospitals and clinics, supporting early diagnosis and reducing the need for invasive blood sampling. This advancement reflects Draeger’s strategic focus on enhancing diagnostic precision in neonatal care through smart, patient-friendly technologies
- In January 2024, Philips Healthcare partnered with a regional government health initiative in Southeast Asia to pilot its Mother & Baby Care Program, incorporating smart neonatal jaundice screening tools in rural healthcare centers. The initiative aims to expand access to early detection and timely treatment in low-resource settings. By integrating portable bilirubin meters and LED phototherapy devices, Philips is addressing regional disparities in neonatal healthcare access
- In December 2023, Natus Medical Incorporated expanded its product line by launching neoBLUE compact, a cost-effective and space-saving phototherapy device tailored for both hospital and home use. With LED technology that delivers consistent irradiance, the device meets global treatment standards while addressing the growing demand for affordable neonatal care solutions in emerging markets
- In November 2023, Nice Neotech Medical Systems Pvt. Ltd., a key player in India’s neonatal equipment market, unveiled a new portable Dual Surface LED Phototherapy System. The device is designed to provide intensive treatment in NICUs and rural clinics, enabling quicker bilirubin breakdown from both sides of the infant’s body. This development underscores the company’s focus on innovation tailored to regional needs and the ongoing expansion of neonatal care in developing countries.
